# US 2021/0275596 A1 · Application of gene profile for cells isolated using fresh-tracer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0275596 A1
- Document ID: US20210275596A1
- Status: Published application
- Kind: A1
- Application number: 17/253,862
- Filed: 2018-07-20
- Published: 2021-09-09
- Earliest claimed: 2018-07-20
- Assignees: Cell2In, Inc.
- Applicants: Cell2In, Inc.
- Inventors: Heun Soo KANG; Hye Mi KIM; Ji Eun SONG; Yingfu YIN; Ji Woong SHIN; Hye Won KANG; Yong Hwan KIM
- Web page: https://patentgrep.com/patent/US20210275596A1

## CPC

- A61K 35/28: Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
- C12N 5/0606: {Pluripotent embryonic cells, e.g. embryonic stem cells [ES] (embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696)}
- A61K 35/545: Embryonic stem cells; Pluripotent stem cells; Induced pluripotent stem cells; Uncharacterised stem cells
- A61P 11/06: Antiasthmatics
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61K 2035/124: {the cells being hematopoietic, bone marrow derived or blood cells}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a therapeutic stem cell composition comprising a stem cell in which the expression level of any one or more genes selected from the group consisting of ACAN, SOX9, AP2, RUNX2, OCN, ALP, OCT4, SOX2, CXCR4, cMET, PDGFRA, PDGFRB, VEGF-R1, VEGF-R2, CSF-1, IDO2, Sox2, Nanog, cMyc, Klf2, Klf4, Rex1, Esrrb, Neurog1, Neurod1, Nkx2.2, Ascl2, Gfap, S100b, Olig2, Neurog2, T, Nkx2.5, Esrrbb, Klf2, Klf4, cTnT, a-Actin, Mlc2v and Runx1 is higher or lower than the expression level of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.

## Claims

### Claim at position 1

1-90. (canceled)

### Claim 91

A therapeutic stem cell in which the expression level of any one or more selected from the group consisting of OCT4, SOX2, cMET, PDGFRA, PDGFRB, VEGF-R1 and VEGF-R2 is higher or lower than the expression level of GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.

### Claim 92 (depends on 91)

The therapeutic stem cell of claim 91, wherein the stem cell is any one type selected from the group consisting of mesenchymal stem cell (MSC), embryonic stem cell (ESC), or embryoid body (EB).

### Claim 93 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) in which the expression level of any one or more genes selected from the group consisting of OCT4, SOX2, cMET, PDGFRA, PDGFRB, VEGF-R1 and VEGF-R2 is lower than the expression level of the GAPDH (glyceraldehyde 3-phosphate dehydrogenase) gene.

### Claim 94 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) whose growth and proliferation are promoted when the expression level of cMET is 0.063- to 0.078-fold of that of GAPDH.

### Claim 95 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) whose engraftment rate, viability and vascular regeneration ability increase when the expression level of PDGFRA is 0.31- to 0.39-fold of that of GAPDH.

### Claim 96 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) whose engraftment rate, viability and vascular regeneration ability increase when the expression level of PDGFRB is 0.45- to 0.56-fold of that of GAPDH.

### Claim 97 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) whose engraftment rate, viability and vascular regeneration ability increase when the expression level of VEGF-R1 is 0.44- to 0.55-fold of that of GAPDH.

### Claim 98 (depends on 92)

The therapeutic stem cell of claim 92, wherein the stem cell is a mesenchymal stem cell (MSC) whose engraftment rate, viability and vascular regeneration ability increase when the expression level of VEGF-R2 is 0.62- to 0.77-fold of that of GAPDH.

### Claim 99 (depends on 91)

A method for treating asthma, the method comprising administering an effective amount of a pharmaceutical composition comprising the therapeutic stem cell according to claim 91 to a patient in need thereof.

### Claim 100 (depends on 91)

A method for treating allergic asthma, the method comprising administering an effective amount of a pharmaceutical composition comprising the therapeutic stem cell according to claim 91 to a patient in need thereof.